| 前收盘价格 | 0.462 |
| 收盘价格 | 0.604 |
| 成交量 | 196,416,463 |
| 平均成交量 (3个月) | 760,832 |
| 市值 | 48,287,784 |
| 价格/销量 (P/S) | 0.210 |
| 52周波幅 | |
| 利润日期 | 12 Nov 2026 |
| 营业毛利率 | -41.02% |
| 营业利益率 (TTM) | -18.89% |
| 稀释每股收益 (EPS TTM) | -1.04 |
| 季度收入增长率 (YOY) | 22.50% |
| 总债务/股东权益 (D/E MRQ) | 1,407.14% |
| 流动比率 (MRQ) | 2.00 |
| 营业现金流 (OCF TTM) | -15.65 M |
| 杠杆自由现金流 (LFCF TTM) | 10.01 M |
| 资产报酬率 (ROA TTM) | -9.57% |
| 股东权益报酬率 (ROE TTM) | -1,552.23% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 看涨 |
| Diagnostics & Research (全球的) | 混合的 | 看涨 | |
| 股票 | MDxHealth SA | 混合的 | 看涨 |
AIStockmoo 评分
1.7
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.67 |
|
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 13.22% |
| 机构持股比例 | 43.04% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Mvm Partners, Llc | 31 Mar 2026 | 4,700,457 |
| Panoramic Capital, Llc | 31 Mar 2026 | 238,668 |
| Landscape Capital Management, L.L.C. | 31 Mar 2026 | 163,655 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合